US9993470 — Combination therapy
Method of Use · Assigned to Aerie Pharmaceuticals Inc · Expires 2034-03-14 · 8y remaining
What this patent protects
This patent protects compounds and compositions for treating glaucoma and/or reducing intraocular pressure, specifically combinations of isoquinoline compounds and prostaglandins or analogs.
USPTO Abstract
Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.
Drugs covered by this patent
- Xalatan (LATANOPROST) · Thea Pharma
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-1524 |
— | Xalatan |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.